Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

eatment periods. Adverse events were generally of mild to moderate severity and occurred in all three treatment groups and the placebo group. The frequency of adverse events was dose-ordered across the 10 mg, 15 mg and 20 mg doses, with the 20 mg group reporting the highest number of events. There were few reports of gastrointestinal complaints in any of the three dose groups.

About Xerostomia

Xerostomia, or dry mouth, is the result of decreased salivary flow and is a symptom of a number of underlying conditions. Causes of dry mouth include Sjogren's syndrome; radiation treatment to the head and neck; and HIV-related salivary gland disease. Xerostomia can also be a side effect of medications and is associated with aging.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates, two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions, including statements regarding the potential of NGX267 as a treatment for xerostomia, the potential of NGX267 to treat xerostomia associated with Sjogren's syndrome, radiation treatment to the head and neck, HIV-related salivary gland disease, aging, or side effects of medication, and the potential t
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and PITTSBURGH , July 27, 2015 /PRNewswire/ ... will hold its extraordinary general meeting of shareholders in connection ... PRGO ; TASE) at the Okura Hotel Amsterdam on Friday, ... Among other agenda items at the extraordinary ... approval, under article 2:107a of the Dutch Civil Code, of ...
(Date:7/27/2015)... , July 20, 2015 ... announced the addition of the "Cardiometabolic Drug ... Afrezza,s discounted pricing is in line with ... critical to the product,s commercial appeal. However, contraindications, ... Afrezza from gaining a sizeable share of the ...
(Date:7/27/2015)...  Linear accelerators used to treat patients with ... adequate space for the equipment itself, but also ... the size and complexity of the technology, full ... of a new vault constitutes a formidable undertaking ... patient treatment: with potential negative long-term effects for ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Accelerating the Design Process for Cancer Treatment Centers 2Accelerating the Design Process for Cancer Treatment Centers 3
... 23, 2011 PharmacoFore, Inc., a privately held ... announced positive results from a Phase I human ... Molecular Delivery™ (Bio-MD™) product candidate, PF329.  Greg Sturmer, ... 2011 BIO Business Forum during the annual BIO ...
... Luminex Corporation (NASDAQ: LMNX ) has ... Most Innovative Company of the Year (for companies with ... Year for the MAGPIX System.  A record number of ... organizations from virtually all company sizes and industries.  In ...
Cached Medicine Technology:PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 2PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 3PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was 4Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System 2Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System 3
(Date:7/27/2015)... ... July 28, 2015 , ... ... as the sports medicine provider for the entire school district including Anderson County ... ACHS Athletic Director Rick Sallee, “Student safety and well-being are a top priority ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of Professional ... VIP Woman of the Year Circle. She is recognized with this prestigious distinction for ... boasting more than 700,000 members and over 200 operating Local Chapters. , “I’m pleased ...
(Date:7/27/2015)... ... July 27, 2015 , ... Interactive health education is ... this year Wound Care Advantage beta launched Luvo University, an online ... Customized learning paths allow for clinicians, physicians, hyperbaric technicians and non-clinical staff ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... transformed the science of the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), ... American Academy of Neurology (AAN). The FSHD care guideline is published today. ...
(Date:7/27/2015)... ... ... Looking to brush up on all the things you should be doing ... enhanced its Dental webpage with new materials, including user-friendly, educational videos, to help members ... to offering our 3.8 million members tools and resources to help them keep a ...
Breaking Medicine News(10 mins):Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 2Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 3Health News:NAPW Inducts Joanne Saniewski, Principal of the Frontier School District's Big Tree Elementary, Into its VIP Woman of the Year Circle 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2
... Leverages Personal Health Care Utilization and Employee Data to ... WHO: Daryl Ashley, senior vice president and general ... Benefits Administration for Workscape, a leading ... Will be a featured presenter in the "Getting Personal -- ...
... and anchor ... depth, ... SN) Endoscopy Division today announced the launch of the,BIORAPTOR 2.3 PK Suture ... is featured at Smith & Nephew Endoscopy,s booth,at the American Academy of ...
... Care,Spending May More Than Double as Hospital Capacity Declines And Baby Boomer ... ... of over 70,million aging baby boomers could overwhelm the U.S. health care ... the,Boom Bust Health Care?," by management consulting firm Tefen USA., A ...
... to Invest in Your Teeth, VOORHEES, N.J., March ... should be similar for 2007. Together with the,government,s economic ... in the pockets of most taxpayers this Spring, it,s ... vacations., But rather than getting away for a ...
... Associate at Kendle ... International, Inc., Joins Catalyst, CORAL GABLES, Fla., March 5 ... the,appointment of Patrick Kenny as Director - Corporate Clinical Compliance.,In ... and GCP compliance of the CROs, clinical contractors and,clinical trial ...
... 1999,OurHealthNetwork.com ( http://www.OurHealthNetwork.com ) has been the,Internet,s leading ... board- certified podiatrists now introduces an exclusive line ... orthotics that not only,provide relief to those who ... their,lifestyles and shoe styles. Now for the first ...
Cached Medicine News:Health News:Upcoming Business Health Agenda 2008 Features Workscape Executive 2Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 2Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 3Health News:Smith & Nephew Endoscopy's BIORAPTOR(TM) 2.3 PK Suture Anchor Provides Secure Repair for Shoulder, Hip Instability 4Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 2Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 3Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 4Health News:Smile When You Get that Refund 2Health News:Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance 2Health News:Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance 3Health News:Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance 4Health News:Unique Line of Custom-Made Orthotics for Sandals and Clogs Cater to Style-Minded Foot Pain Sufferers 2
Well established test for children but suitable for disabled people, those with learning difficulties or patients who do not share a common language with the examiner....
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
This test displays normal protan, deutan and tritan colors, differentiation is stronger in the red/green., ,Significant tritan defects may be detected if used in conjunction with the Ishihara. Th...
The New Vantage Plus. The PLUS gives you: ,P Premium intelligent optics ,L Lighter weight and brighter images ,U Unique wireless patented technology ,S Smaller and more compact size ...
Medicine Products: